BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xenotech Introduces CryostaX(TM), an Innovative Single-Freeze Source for Human Hepatocytes


12/21/2009 1:20:28 PM

LENEXA, KS--(Marketwire - December 21, 2009) - XenoTech L.L.C., specialists in evaluation of drug candidates in vitro, is proud to introduce the latest innovation in the field of cryopreserved pooled human hepatocytes: CryostaX™.

CryostaX™ is the largest single-freeze pool of cryopreserved human hepatocytes. This patent-pending single-freeze product offers large lots of hepatocytes that allow long-term predictable results. Like all of the XenoTech products, CryostaX™ undergoes a thorough data review to ensure a dependable, high-quality source of human hepatocytes -- an integral part of any drug development program.

"CryostaX™ is an example of our continuous commitment to provide the best products to advance in vitro drug development research," said Andrew Parkinson, XenoTech's CEO/Chief Scientific Officer.

XenoTech L.L.C. is a Contract Research Organization with years of expertise in optimizing in vitro test systems and study designs to meet the ever-changing demands of scientific achievement.

"We're committed to producing high quality scientific tools that provide great value for pharmaceutical researchers," said Parkinson. "In addition to quality and value offered today, CryostaX™ allows for future customization of pooled human hepatocytes for the in-depth pursuit of safe drug candidates."

About XenoTech L.L.C.

XenoTech, founded by Dr. Andrew Parkinson in 1994, is a Contract Research Organization with unparalleled experience and expertise in evaluating drug candidates as substrates, inhibitors and inducers of cytochrome P450 enzymes. The Company offers a variety of in vitro contract studies for drug candidate evaluation, as well as an extensive selection of products for drug metabolism research. XenoTech's product selection includes a wide range of high-quality in vitro test systems, from subcellular fractions and hepatocytes to recombinant enzymes and transporter membranes. The Company can also prepare and deliver custom-designed products and services in response to client requests. XenoTech is based in Lenexa, Kansas, U.S.A. and is a division of Sekisui Medical Company. For additional information, please email info@xenotechllc.com or refer to the company's web site at www.xenotechllc.com.


For More Information Contact:
XenoTech L.L.C.
info@xenotechllc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES